¼¼°èÀÇ Ç÷¾×°Ë»ç ½ÃÀå
Blood Testing
»óǰÄÚµå : 1785860
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 206 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,242,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,727,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ç÷¾×°Ë»ç ½ÃÀåÀº 2030³â±îÁö 1,431¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 933¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Ç÷¾×°Ë»ç ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 7.4%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 1,431¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ±Û·çÄÚ¿À½º °Ë»ç´Â CAGR 7.2%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 262¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. A1C °Ë»ç ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 6.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 254¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ç÷¾×°Ë»ç ½ÃÀåÀº 2024³â¿¡ 254¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 299¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 11.4%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.8%¿Í 7.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Ç÷¾×°Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Ç÷¾× °Ë»ç°¡ Çö´ë ÀÇ·á¿¡ ÇʼöÀûÀÎ Á¸Àç°¡ µÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Ç÷¾× °Ë»ç´Â ÀÇ·á ºÐ¾ß¿¡¼­ °¡Àå ±âº»ÀûÀÎ Áø´Ü ÀýÂ÷ Áß ÇϳªÀ̸ç, ȯÀÚÀÇ Àü¹ÝÀûÀÎ °Ç°­ »óÅÂ, Áúº´ »óÅ ¹× Ä¡·á ¹ÝÀÀ¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ÀÏ»óÀûÀÎ °ËÁøºÎÅÍ º¹ÀâÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®¿¡ À̸£±â±îÁö Ç÷¾× °Ë»ç´Â °¨¿°, ´ë»çÀÌ»ó, ½ÉÇ÷°ü Áúȯ, ¾Ï, ÀÚ°¡¸é¿ªÁúȯÀÇ Áø´Ü¿¡ »ç¿ëµË´Ï´Ù. ¸¸¼ºÁúȯ Áõ°¡, ¿¹¹æÀÇÇп¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áø´Ü±â¼úÀÇ ¹ßÀüÀº º´¿ø, Áø´Ü¿¬±¸¼Ò, ÇöÀå Áø·á¼Ò¿¡¼­ Ç÷¾× °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº ½Å¼ÓÇϰí Á¤È®ÇÑ Ç÷¾× °Ë»çÀÇ Á߿伺À» ´õ¿í ºÎ°¢½ÃÄ×°í, Áø´Ü ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, PCR ±â¹Ý ¹× Ç÷ûÇÐÀû °Ë»ç¿Í °°Àº ÷´Ü ±â¼úÀÇ Ã¤ÅÃÀ¸·Î À̾îÁ³½À´Ï´Ù. ¶ÇÇÑ ¸ÂÃãÀÇ·á¿Í Á¤¹ÐÁø´ÜÀº ƯÈ÷ Á¾¾çÇÐ ¹× À¯ÀüÁúȯ¿¡¼­ Ç¥ÀûÄ¡·á¸¦ À¯µµÇÏ´Â Ç÷¾×°Ë»çÀÇ ¿ªÇÒÀ» È®´ëÇß½À´Ï´Ù. ÇコÄɾ Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¿¹¹æ ÀÇ·á·Î ÀüȯµÊ¿¡ µû¶ó ½Å¼ÓÇϰí Á¤È®Çϸç ÃÖ¼Ò Ä§½ÀÀûÀÎ Ç÷¾× °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº Ç÷¾× °Ë»ç¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

Ç÷¾× °Ë»ç ±â¼úÀÇ Áß¿äÇÑ Çõ½ÅÀº Á¤È®¼º, ¼Óµµ, ÆíÀǼºÀ» Çâ»ó½ÃÄÑ È¯ÀÚ¿Í ÀÇ·áÁø¿¡°Ô Áø´ÜÀ» ´õ¿í Ä£¼÷ÇÏ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß¿¡¼­ °¡Àå ȹ±âÀûÀÎ ¹ßÀü Áß Çϳª´Â ¾×ü»ý°Ë ±â¼úÀÇ °³¹ßÀÔ´Ï´Ù. ¾×ü»ý°ËÀº Ç÷¾×³» ¼øÈ¯ Á¾¾ç DNA(ctDNA)¿Í ¹ÙÀÌ¿À¸¶Ä¿¸¦ ÅëÇØ ¾Ï ¹× ±âŸ Áúº´À» °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾×ü»ý°ËÀº ±âÁ¸ÀÇ Á¶Á÷ »ý°ËÀ» ´ëüÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû °Ë»ç¹ýÀ¸·Î ¾ÏÀÇ Á¶±â ¹ß°ß, Áúº´ ¸ð´ÏÅ͸µ, Ä¡·á È¿°ú Æò°¡¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

Ç÷¾× °Ë»çÀÇ ¶Ç ´Ù¸¥ ºñ¾àÀûÀÎ ¹ßÀüÀº ÇöÀå Áø·á(POC) ¹× °¡Á¤¿ë Ç÷¾× °Ë»ç ±â±âÀÇ ÃâÇöÀÔ´Ï´Ù. ÀÌ ÈÞ´ë¿ë, »ç¿ëÀÚ Ä£È­ÀûÀÎ ½Ã½ºÅÛÀº ¿ÏÀüÇÑ ½ÇÇè½Ç ¼³Ä¡ ¾øÀ̵µ Æ÷µµ´ç, ÄÝ·¹½ºÅ×·Ñ, °¨¿°, ÀÀ°í ¼öÁØÀ» ½Å¼ÓÇÏ°Ô °Ë»çÇÒ ¼ö ÀÖ´Â ÈÞ´ë¿ë ½Ã½ºÅÛÀÔ´Ï´Ù. ¶ÇÇÑ ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)ÀÌ Áø´Ü Ç÷§Æû¿¡ ÅëÇÕµÇ¾î °Ë»ç ÇØ¼®À» °­È­Çϰí, ¿¹Ãø ºÐ¼®À» °³¼±Çϸç, Áø´Ü ¿À·ù¸¦ ÁÙÀ̰í ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º ±â¼ú°ú ·¦¿ÂĨ ±â¼úÀ» äÅÃÇÏ¿© ½Ã·á 󸮸¦ °£¼ÒÈ­ÇÏ¿© ÃÖ¼ÒÇÑÀÇ ½Ã·á·®À¸·Î ½Å¼ÓÇϰí ÀÚµ¿È­µÈ Ç÷¾× ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ¹ßÀüÀº Áø´ÜÀÇ ½Å¼ÓÈ­, Á¤¹ÐÈ­, ȯÀÚ Áß½ÉÀÇ ÀǷḦ ½ÇÇöÇϰí, Á¤¼¼¸¦ Å©°Ô º¯È­½Ã۰í ÀÖ½À´Ï´Ù.

Ç÷¾× °Ë»ç »ê¾÷ÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â ½ÃÀå µ¿ÇâÀº?

¿¹¹æÀû °Ç°­°ü¸®¿Í Á¤±â°ËÁø¿¡ ´ëÇÑ Á߿伺ÀÌ ³ô¾ÆÁö¸é¼­ Ç÷¾×°Ë»ç ½ÃÀåÀ» ÁÖµµÇÏ´Â °¡Àå ¿µÇâ·Â ÀÖ´Â µ¿Çâ Áß ÇϳªÀÔ´Ï´Ù. ´ç´¢º´, ½ÉÇ÷°üÁúȯ, °£Áúȯ µî »ýȰ½À°üº´ÀÌ Áõ°¡Çϸ鼭 Á¶±â¹ß°ß°ú À§ÇèÆò°¡¸¦ À§ÇØ Á¤±âÀûÀÎ Ç÷¾×°Ë»ç¸¦ ¹Þ´Â »ç¶÷µéÀÌ ´Ã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ»çÀÇ ¼Ò°³ ¾øÀÌ ¿Â¶óÀÎÀ¸·Î °Ë»ç¸¦ ÁÖ¹®ÇÒ ¼ö ÀÖ´Â DTC(Direct-to-Consumer) ¼­ºñ½ºÀÇ ÀÌ¿ë °¡´É¼ºÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¼­ºñ½ºµéÀº Áý¿¡¼­ ½Ã·á äÃë¿Í µðÁöÅÐ °á°ú ÇØ¼®ÀÌ °¡´ÉÇÏ¿© °Ç°­À» Áß½ÃÇÏ´Â ¼ÒºñÀڵ鿡°Ô ´õ ³ôÀº ÆíÀǼº°ú Á¢±Ù¼ºÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀåÀ» Çü¼ºÇÏ´Â ¶Ç ´Ù¸¥ ÁÖ¿ä µ¿ÇâÀº À¯ÀüÀÚ ¹× ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý Ç÷¾× °Ë»çÀÇ È®´ëÀÔ´Ï´Ù. Á¤¹ÐÀÇ·á°¡ ´ëÁßÈ­µÇ¸é¼­ Ç÷¾×°Ë»ç´Â Áúº´ÀÇ À¯ÀüÀû ¼ÒÀÎÀ» ÆÄ¾ÇÇϰí, Ç¥Àû Ä¡·á¸¦ À¯µµÇϰí, Áúº´ÀÇ ÁøÇàÀ» ¸ð´ÏÅ͸µÇÏ´Â µ¥ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀÇ·á ¹× ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ ºÎ»óÀ¸·Î µðÁöÅÐ Çコ Ç÷§Æû°ú µ¿±âÈ­µÇ¾î ½Ç½Ã°£ ÃßÀû ¹× ÀÇ»çÀÇ Áø·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â Ä¿³ØÆ¼µå Ç÷¾× °Ë»ç ÀåÄ¡ÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. Ç×±ÕÁ¦ ³»¼º µî »õ·Î¿î À§ÇùÀ» Æ÷ÇÔÇÑ °¨¿°¼º ÁúȯÀÇ °¨½Ã¸¦ À§ÇÑ Àü ¼¼°èÀÇ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½Å¼ÓÇϰí 󸮷®ÀÌ ³ôÀº Ç÷¾× °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Ç÷¾× °Ë»ç ½ÃÀå Àü¸Á¸¦ Çü¼ºÇÏ´Â ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

Ç÷¾× °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº Áúº´ÀÇ È®»ê, Áø´Ü ±â¼úÀÇ ¹ßÀü, ÀÇ·á ÅõÀÚ Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß Çϳª´Â ¸¸¼ºÁúȯ ¹× °¨¿°¼º ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ Á¶±â¿¡ Á¤È®ÇÑ Áø´ÜÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. Àü ¼¼°è Á¤ºÎ¿Í ÀÇ·á ±â°üÀº Áúº´ ¿¹¹æ°ú Á¶±â °³ÀÔÀ» ¿ì¼±¼øÀ§·Î »ï°í ÀÖÀ¸¸ç, ÀÌ´Â Áý´Ü°Ç°­°ü¸®¸¦ À§ÇÑ ÀÏ»óÀûÀÎ Ç÷¾× °Ë»ç äÅÃÀ» È®´ëÇÏ´Â Ãß¼¼·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

½ÃÀåÀ» Çü¼ºÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿ä¼Ò´Â ºÐ»êÇü ¹× ÀçÅà °Ë»ç ¼Ö·ç¼ÇÀ¸·ÎÀÇ ÀüȯÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¼ÒºñÀÚµéÀÌ º¸´Ù Æí¸®ÇÏ°í »ç¿ëÇϱ⠽¬¿î °ÍÀ» ¿øÇϹǷΠÁø´Ü ±â¾÷Àº ½ÇÇè½ÇÀ» ¹æ¹®ÇÏÁö ¾Ê°íµµ ºü¸¥ °á°ú¸¦ Á¦°øÇÏ´Â ÈÞ´ë¿ë, »ç¿ëÀÚ Ä£È­ÀûÀÎ Ç÷¾× °Ë»ç Àåºñ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¥ÀÌÅÍ ºÐ¼®°ú AI ±â¹Ý Áø´ÜÀÇ ¹ßÀüÀ¸·Î °Ë»ç Á¤È®µµ°¡ Çâ»óµÇ¾î ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ °³ÀÎÈ­µÈ À§Çèµµ Æò°¡¿Í ¿¹Ãø ¸ðµ¨¸µÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¼¼°è ÇコÄɾî ȯ°æÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, Çõ½Å, °Ç°­ ÀÎ½Ä Áõ°¡, º¸´Ù È¿À²ÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ Ãß±¸·Î ½ÃÀå ȯ°æÀº È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

°Ë»ç À¯Çü(±Û·çÄÚ¿À½º °Ë»ç, A1C °Ë»ç, Á÷Á¢ LDL °Ë»ç, ÁöÁú ÆÐ³Î °Ë»ç, Àü¸³¼± ƯÀÌ Ç׿ø °Ë»ç, COVID-19 °Ë»ç, BUN °Ë»ç, ºñŸ¹Î D°Ë»ç, °©»ó¼± ÀÚ±Ø È£¸£¸ó(TSH) °Ë»ç, Ç÷û ´ÏÄÚÆ¾/ÄÚÆ¼´Ñ °Ë»ç, °í°¨µµ CRP °Ë»ç, Å×½ºÅ佺Å×·Ð °Ë»ç, ALT °Ë»ç, ÄÚ¸£Æ¼¼Ö °Ë»ç, Å©·¹¾ÆÆ¼´Ñ °Ë»ç, AST °Ë»ç, ±âŸ Ç÷¾×°Ë»ç)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø·Î ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Blood Testing Market to Reach US$143.1 Billion by 2030

The global market for Blood Testing estimated at US$93.3 Billion in the year 2024, is expected to reach US$143.1 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Glucose Testing, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$26.2 Billion by the end of the analysis period. Growth in the A1C Testing segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.4 Billion While China is Forecast to Grow at 11.4% CAGR

The Blood Testing market in the U.S. is estimated at US$25.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$29.9 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Blood Testing Market - Key Trends & Drivers Summarized

Why Is Blood Testing Becoming More Essential in Modern Healthcare?

Blood testing is one of the most fundamental diagnostic procedures in healthcare, providing critical insights into a patient’s overall health, disease status, and treatment response. From routine screenings to complex biomarker analysis, blood tests are used for diagnosing infections, metabolic disorders, cardiovascular diseases, cancers, and autoimmune conditions. The increasing prevalence of chronic diseases, rising awareness of preventive healthcare, and advancements in diagnostic technology have fueled the demand for blood testing in hospitals, diagnostic laboratories, and point-of-care settings.

The COVID-19 pandemic further highlighted the importance of rapid and accurate blood testing, leading to increased investments in diagnostic infrastructure and the adoption of advanced technologies, such as PCR-based and serological tests. Additionally, personalized medicine and precision diagnostics have expanded the role of blood testing in guiding targeted therapies, particularly in oncology and genetic disorders. As healthcare systems continue to shift toward early disease detection and preventive care, the demand for fast, accurate, and minimally invasive blood testing solutions is expected to rise significantly.

How Are Technological Advancements Transforming Blood Testing?

Significant innovations in blood testing technology are enhancing accuracy, speed, and convenience, making diagnostics more accessible to patients and healthcare providers. One of the most transformative advancements in this field is the development of liquid biopsy technology, which enables the detection of cancer and other diseases through circulating tumor DNA (ctDNA) and biomarkers in the blood. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, allowing for early cancer detection, disease monitoring, and treatment response evaluation.

Another breakthrough in blood testing is the emergence of point-of-care (POC) and home-based blood testing devices. These portable and user-friendly systems enable rapid testing for glucose, cholesterol, infectious diseases, and coagulation levels without requiring a full laboratory setup. Additionally, artificial intelligence (AI) and machine learning (ML) are being integrated into diagnostic platforms to enhance test interpretation, improve predictive analytics, and reduce diagnostic errors. The adoption of microfluidic and lab-on-a-chip technologies has also streamlined sample processing, enabling rapid and automated blood analysis with minimal sample volumes. As these technological advancements continue to evolve, they are revolutionizing the blood testing landscape, making diagnostics faster, more precise, and increasingly patient-centric.

Which Market Trends Are Driving Growth in the Blood Testing Industry?

The growing emphasis on preventive healthcare and routine screening is one of the most influential trends driving the blood testing market. With a rise in lifestyle-related conditions such as diabetes, cardiovascular diseases, and liver disorders, more individuals are undergoing regular blood tests for early detection and risk assessment. The increasing availability of direct-to-consumer (DTC) blood testing services, where individuals can order tests online without a physician’s referral, is also fueling market expansion. These services offer at-home sample collection and digital result interpretation, providing greater convenience and accessibility for health-conscious consumers.

Another key trend shaping the market is the expansion of genetic and biomarker-based blood tests. As precision medicine gains traction, blood testing is being used to identify genetic predispositions to diseases, guide targeted treatments, and monitor disease progression. Additionally, the rise of telemedicine and remote patient monitoring has accelerated the adoption of connected blood testing devices that sync with digital health platforms, enabling real-time tracking and physician consultations. The growing global focus on infectious disease surveillance, including emerging threats such as antimicrobial resistance, is also driving demand for rapid and high-throughput blood testing solutions.

What Are the Key Growth Drivers Shaping the Future of the Blood Testing Market?

The growth in the blood testing market is driven by several critical factors, including rising disease prevalence, advancements in diagnostic technology, and increasing healthcare investments. One of the primary growth drivers is the rising incidence of chronic and infectious diseases, which has led to an increased need for early and accurate diagnosis. Governments and healthcare organizations worldwide are prioritizing disease prevention and early intervention, leading to greater adoption of routine blood testing for population health management.

Another crucial driver shaping the market is the increasing shift toward decentralized and at-home testing solutions. As consumers demand greater convenience and accessibility, diagnostic companies are investing in portable, user-friendly blood testing devices that provide rapid results without the need for laboratory visits. Additionally, advancements in data analytics and AI-driven diagnostics are enhancing test accuracy, enabling personalized risk assessments and predictive modeling for various diseases. As the global healthcare landscape continues to evolve, the blood testing market is expected to expand, driven by innovation, increasing health awareness, and the continuous pursuit of more efficient, cost-effective diagnostic solutions.

SCOPE OF STUDY:

The report analyzes the Blood Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Glucose Testing, A1C Testing, Direct LDL Testing, Lipid Panel Testing, Prostate-specific Antigen Testing, COVID-19 Testing, BUN Testing, Vitamin-D Testing, Thyroid-stimulating Hormone (TSH) Testing, Serum Nicotine/Cotinine Testing, High sensitivity CRP Testing, Testosterone Testing, ALT Testing, Cortisol Testing, Creatinine Testing, AST Testing, Others Blood Tests)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â